Clinical Trial Update: Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluated immunogenicity, reactogenicity, and safety of a double viral vaccine for measles and rubella. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Rubella

Drugs mentioned

• Double Viral Vaccine (MR) (measles-rubella vaccine)

Snippet

Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Conditions: Rubella, Measles | Phase 2, Phase 3 | Status: COMPLETED